Skip to content

Drug interactions

Aprepitant + Palovarotene

Severity: Major

Aprepitant and Palovarotene: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Aprepitant may increase palovarotene exposure through CYP3A4 inhibition. This may increase retinoid toxicity such as mucocutaneous effects and premature epiphyseal closure risk in children.

What this interaction means in plain words

Aprepitant and Palovarotene can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Aprepitant belongs to Gastrointestinal Tract; Palovarotene belongs to Miscellaneous.

Evidence level: Moderate

Why it happens

Inhibition of CYP3A4-mediated palovarotene metabolism by aprepitant.

What to do

Avoid the combination if possible. If unavoidable, reduce the palovarotene dose by 50% and monitor for retinoid adverse effects.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Aprepitant and Palovarotene, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Aprepitant with Palovarotene?

MediHelp rates the interaction as major. Aprepitant and Palovarotene can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Aprepitant may increase palovarotene exposure through CYP3A4 inhibition. This may increase retinoid toxicity such as mucocutaneous effects and premature epiphyseal closure risk in children.

How serious is the interaction between Aprepitant and Palovarotene?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination if possible. If unavoidable, reduce the palovarotene dose by 50% and monitor for retinoid adverse effects.

What other medicines interact with Aprepitant?

MediHelp also lists interactions of Aprepitant with, for example, Lomitapide, Pimozide, Avapritinib. The full list is on the Aprepitant page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in